Bone metabolism in 2012: Novel osteoporosis targets
- PMID: 23296178
- DOI: 10.1038/nrendo.2012.252
Bone metabolism in 2012: Novel osteoporosis targets
Abstract
Researchers are trying to develop more efficient and safer antifracture treatments. Besides the ongoing promising clinical trials involving antibodies to the Wnt antagonist sclerostin or inhibition of the osteoclast enzyme cathepsin K, the year 2012 has seen several novel osteoporosis targets identified by using different methodological approaches.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
